Hey clyde, I think that you may have already answered your own...

Hey clyde,

I think that you may have already answered your own question. Before SC can market it then he really needs the product and results (data pack) to take to the market.

I think SC has done some marketing previously, remember the small investor show and those meetings with the Global Fund in New York. One of the things that I remember from the last AGM was that Jooste did say that SC wanted to get everything squared away before he went back to the New York boys. Geez, we must be geting close to having everything squared away.

I've been thinking - if there is anything in the posters that will be put up at the conference that relate to Ph III data (and I know it's a big if) then EMS will need to notify the market, and I reckon it would have to be classed as mkt sensitive - so if there is a mkt sensitive ann. before trade tomorrow morning - it could be an interesting day.

Any indication (even some preliminary findings) that artimist is superior to IV quinine has to be a shot in the arm - so to speak - for the share price. Although I have noticed a couple of positive ann.s come out on biospecs recently without any re-rate? So who knows.

Here's a useless bit of trivia. The day after Reuters named artimist in the top 5 drugs currently in PhIII trials - nearly 120 millions shares changed hands.

Was buying smalls today and looking (hopefully) towards tomorrow

bluebush